Perioperative Management of Apixaban

Preoperative Management

The American College of Chest Physicians recommends that apixaban be discontinued 1 day before surgery and resumed 24 hours after surgery if adequate hemostasis is achieved in patients with atrial fibrillation undergoing cholecystectomy 1, 2
Cholecystectomy is considered a low-to-moderate bleeding risk procedure, requiring apixaban discontinuation for 1 day before surgery, as suggested by the American College of Chest Physicians and other guidelines 1, 2
For patients with normal renal function, the last dose of apixaban should be taken on the morning of the day before the planned procedure, according to the Anaesthesia journal 3, 2
The timing of apixaban discontinuation allows approximately 2-3 half-lives to elapse, resulting in minimal residual anticoagulant effect at the time of surgery, as reported in the Blood journal 4, 1

The European Heart Journal suggests resuming apixaban on the day after surgery (24 hours postoperatively) at the usual dose (5 mg twice daily) for cholecystectomy (low-to-moderate bleeding risk) 4, 1
Ensure at least 6-24 hours have elapsed after the end of the procedure to allow sufficient time for wound hemostasis, as recommended by the European Heart Journal 5, 2

Monitor for signs of bleeding after resumption of apixaban, as advised by the American College of Chest Physicians 1
The PAUSE study demonstrated low 30-day postoperative rates of arterial thromboembolism (0.16%) and major bleeding (1.35%) with standardized perioperative apixaban management, as published in the Chest journal 6, 7
If apixaban cannot be restarted promptly due to bleeding concerns, consider mechanical thromboprophylaxis methods until anticoagulation can be safely resumed, according to the Anaesthesia journal 3

Avoid unnecessarily prolonged interruption of anticoagulation, which increases thromboembolic risk, as warned by the American College of Chest Physicians 1
Ensure clear communication with the surgical team about the timing of apixaban discontinuation and resumption to avoid confusion, as emphasized by the European Heart Journal 5
Develop and implement institutional guidelines for perioperative anticoagulation management to ensure consistent practice, as recommended by the European Heart Journal 5, 8

The French GIHP guidelines recommend resuming apixaban therapy "six hours or more after the end of the invasive procedure" for low-risk procedures, such as dental extractions, cataract surgery, and superficial dermatologic procedures, as soon as adequate hemostasis has been established 9, 10
For low bleeding risk procedures, apixaban can be restarted at 6-8 hours post-procedure if immediate and complete hemostasis is achieved, according to the European Heart Journal 9, 11
The European Heart Rhythm Association recommends resuming apixaban "on the day after surgery (24 hours postoperatively)" for low-to-moderate risk procedures, but allows up to 48-72 hours for higher risk procedures, such as major abdominal surgery and major orthopedic surgery 11, 10

The European Heart Journal suggests considering prophylactic-dose LMWH starting 6-8 hours post-procedure for procedures requiring immobilization or those at very high bleeding risk where full-dose apixaban restart must be delayed, and transitioning to full-dose apixaban at 48-72 hours once bleeding risk diminishes 11

The European Heart Journal recommends restarting apixaban immediately post-procedure without interruption for left atrial catheter ablation procedures, as uninterrupted anticoagulation reduces both thromboembolic and bleeding complications 10

The American College of Cardiology recommends not unnecessarily prolonging anticoagulation interruption beyond what is required for hemostasis, as this increases stroke risk in AFib patients (annual stroke risk 2-7% depending on CHA₂DS₂-VASc score) 11, 12
The European Heart Journal advises against routinely bridging with heparin products, as the BRIDGE trial demonstrated increased bleeding without thrombotic benefit 9, 12
The American College of Cardiology notes that apixaban achieves therapeutic anticoagulation rapidly (within 3-4 hours of dosing), unlike warfarin which requires days 12
The European Heart Journal and the American College of Cardiology recommend ensuring institutional protocols are in place for consistent perioperative management 10, 13